Trials / Unknown
UnknownNCT01612286
Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
A Phase II Clinical Study of Endostar Combination With Chemotherapy in the Metastatic Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
Detailed description
To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse reaction of recombinant human endostatin (endostar) combined with chemotherapy to the metastatic nasopharyngeal carcinoma (NPC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | endostatin | Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2013-12-01
- Completion
- 2014-05-01
- First posted
- 2012-06-05
- Last updated
- 2014-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01612286. Inclusion in this directory is not an endorsement.